Scorpius Holdings (SCPX)
OTHER OTC:SCPX
Top Page
Scorpius Holdings
(OTC:SCPX)
Select Model
Select Model
Rating:40Underperform
Price Target:
<$0.01
▼(-55.00% Downside)
Action:ReiteratedDate:01/30/26
The score is held down primarily by weak financial performance (declining revenue, persistent losses, negative free cash flow, and high leverage). Technicals also skew bearish with price below key moving averages and negative MACD. Valuation provides limited support because a negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Diversified business model
Scorpius operates across technology, real estate and renewable energy and earns fees, dividends and capital gains. This multi‑stream model reduces reliance on a single market cycle and gives management flexibility to reallocate capital to higher-growth portfolio areas over the next 2–6 months and beyond.
Negative Factors
Very high leverage
A 4.53 debt‑to‑equity ratio indicates substantial leverage that elevates refinancing, interest and covenant risk. High structural leverage limits strategic flexibility, increases default probability if cash flow remains weak, and magnifies losses to equity holders during prolonged revenue weakness.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
Scorpius operates across technology, real estate and renewable energy and earns fees, dividends and capital gains. This multi‑stream model reduces reliance on a single market cycle and gives management flexibility to reallocate capital to higher-growth portfolio areas over the next 2–6 months and beyond.
Read all positive factors
Scorpius Holdings (SCPX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.25M
Dividend YieldN/A
Average Volume (3M)5.55K
Price to Earnings (P/E)―
Beta (1Y)-5.31
Revenue Growth-69.81%
EPS Growth88.78%
CountryUS
Employees90
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding61,142,710
10 Day Avg. Volume3,056
30 Day Avg. Volume5,554
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.64
Price to Sales (P/S)2.66
P/FCF Ratio-0.62
Enterprise Value/Market Cap14.21
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-342
Revenue Forecast (FY)$10.00M
Scorpius Holdings Business Overview & Revenue Model
Company Description
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimizat...
How the Company Makes Money
Scorpius Holdings generates revenue through multiple streams, primarily from its strategic investments in various sectors. The company earns income by acquiring stakes in high-potential startups and established businesses, benefiting from capital ...
Scorpius Holdings Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 227.54B | 6.24M | 6.99M | 5.98M | 2.11M | 2.95M |
| Gross Profit | 13.87B | 3.05M | -2.22M | -420.02K | 1.42M | 2.95M |
| EBITDA | -5.78T | -26.22M | -33.99M | -39.29M | -34.86M | -24.59M |
| Net Income | -4.08T | -32.81M | -45.22M | -43.43M | -35.07M | -26.05M |
Balance Sheet | ||||||
| Total Assets | 20.77M | 39.18M | 51.04M | 104.40M | 120.96M | 124.19M |
| Cash, Cash Equivalents and Short-Term Investments | 600.79K | 2.38M | 2.39M | 39.03M | 96.38M | 111.77M |
| Total Debt | 18.12M | 28.55M | 14.04M | 9.30M | 1.93M | 1.85M |
| Total Liabilities | 27.75M | 37.50M | 22.74M | 31.96M | 8.93M | 8.70M |
| Stockholders Equity | -1.33T | 6.30M | 31.40M | 73.92M | 113.11M | 116.24M |
Cash Flow | ||||||
| Free Cash Flow | -9.75T | -26.88M | -33.52M | -25.82M | -40.03M | -22.36M |
| Operating Cash Flow | -9.69T | -26.01M | -31.53M | -5.70M | -38.13M | -22.02M |
| Investing Cash Flow | 58.26B | 1.21M | 32.24M | 10.99M | 9.77M | -95.42M |
| Financing Cash Flow | 9.19T | 25.64M | -8.95M | -4.91M | 25.49M | 119.33M |
Scorpius Holdings Risk Analysis
Scorpius Holdings disclosed 48 risk factors in its most recent earnings report. Scorpius Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scorpius Holdings Peers Comparison
UnderperformOutperform
Sector (51)
SCPX
Scorpius Holdings
0.02
-0.14
-87.26%
SCNI
Scinai Immunotherapeutics
0.60
-2.30
-79.28%
ADTX
Aditxt
0.88
-5,572.28
-99.98%
CERO
CERo Therapeutics Holdings
0.03
-15.27
-99.78%
PBM
Psyence Biomedical
2.63
-30.00
-91.94%
CDT
CDT Equity
0.43
-91.73
-99.53%
Scorpius Holdings Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Scorpius Holdings completes major asset foreclosure disposition
Negative
Jan 29, 2026
On December 10, 2025, Scorpius Holdings, Inc. had substantially all of its non-cash assets tied to its CDMO and RD operations foreclosed upon in an Article 9 Uniform Commercial Code sale conducted by a collateral agent on behalf of secured notehol...
Private Placements and Financing
Scorpius Holdings issues new short-term institutional debt
Negative
Jan 13, 2026
On December 16, 17 and 30, 2025, and January 8, 2026, Scorpius Holdings, Inc. issued four non-convertible promissory notes to an institutional investor with an aggregate principal of roughly $239,500, each bearing 5% annual interest, a 15% princip...
Private Placements and Financing
Scorpius Holdings Issues Amended Convertible Promissory Note
Neutral
Dec 3, 2025
On December 2, 2025, Scorpius Holdings, Inc. issued a second amended and restated 1% convertible promissory note for $2,250,000 to Elusys Holdings Inc., a company controlled by its CEO, Jeffrey Wolf. This note extends the maturity date from Septem...
Private Placements and Financing
Scorpius Holdings Issues Third Promissory Note
Neutral
Dec 2, 2025
On November 25, 2025, Scorpius Holdings issued a non-convertible promissory note of $33,000, followed by another on November 26, 2025, for $630,020, and a third on December 1, 2025, for $134,000, all to an institutional investor. These notes accru...
Private Placements and Financing
Scorpius Holdings Issues $122,000 Promissory Note
Neutral
Nov 25, 2025
On November 20, 2025, Scorpius Holdings issued a non-convertible promissory note valued at $122,000 to an institutional investor, with a 5% annual interest rate and a maturity date of May 20, 2026, or upon the occurrence of a corporate event or de...
Private Placements and Financing
Scorpius Holdings Issues Promissory Notes for $1.36 Million
Neutral
Nov 17, 2025
Scorpius Holdings issued four non-convertible promissory notes in October and November 2025 to an institutional investor, totaling approximately $1.36 million. Each note accrues interest at 5% per annum and includes a 15% premium payment upon matu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.